Digest

US new drug approvals The US Food and Drug Administration has granted marketing approval to several compounds ahead of their European regulatory counterpart. Lacosamide (Vimpat) is now approved as monotherapy for partial onset seizures in patients aged over 17. In Europe it is currently limited to adjunctive therapy, though a monotherapy indication will be pursued pending the outcome of a comparative trial against carbamazepine. Peginterferon beta‐1a (Plegridy), administered as a fortnightly subcutaneous injection, has been approved for relapsing forms of multiple sclerosis. Eliglustat (Cerdelga) has been approved for the treatment of type 1 Gaucher's disease; by contrast with enzyme replacement therapies, it is given by mouth.
Source: Progress in Neurology and Psychiatry - Category: Neurology Tags: Digest Source Type: research